AKBA · Akebia Therapeutics, Inc.

Track AKBA — free

$0.88 +0.01 (+1.06%)

Russell 2000 member Rebalance outlook locked

Market Cap

$244.05M

277.11M

Volume · Oct 1 4.52M Avg daily vol (3M) 6.02M

Up next

Next earnings call

Nov 6, 2026 Est · unconfirmed · in 5 wks

Latest filing: 10-Q

filed Aug 5, 2026

Q2 2026 earnings call transcript

call held Aug 5, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$219.06M

Trailing 12 months

Net income (TTM)

−$29.67M

Trailing 12 months

Revenue growth YoY

-21.4%

Year over year

Operating margin

-6.9%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

16.5%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

-0.6%

Year over year · fewer shares

Price change (1Y)

-66.3%

Trailing year

Short interest

7.4%

Latest settlement · 2.8 days to cover

View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 5, 2026

Q2 FY26

TL;DR. Akebia reported strong sequential Vafseo revenue and patient growth, and announced a positive interim VOICE trial result for Vafseo versus ESAs on mortality/hospitalization, while guiding 2027 Vafseo revenue to decline on planned price cuts after loss of tadapa exclusivity; Auryxia revenue continued to fall, driving a quarterly net loss.

Bullish

+ Vafseo Q2 net product revenue grew 34% sequentially to $21.3 million, with over 10,500 patients on therapy (a 41% sequential increase) and ~1,200 prescribers.
+ VOICE interim analysis met stopping criteria, showing Vafseo statistically superior to ESAs on the composite of all-cause mortality and hospitalization (win odds 1.16; p=0.0016).
+ Phase 2 basket trial of ebribafusp in IgA nephropathy, lupus nephritis, and C3 glomerulopathy initiated, with initial data expected in 2027.
+ Vafseo IP portfolio strengthened with a new Orange Book-listed patent and a potential 5-year term extension, with portfolio expirations out to 2036.

Bearish

− Q2 swung to a net loss of $8.9 million from net income of $0.2 million a year ago, driven by lower revenue and higher expenses including a $1.9 million restructuring charge.
− Management expects 2027 Vafseo revenue to decline versus 2026 due to a planned price reduction after expected end of tadapa on December 31, 2026.
− Auryxia revenue fell to $25.5 million from $47.2 million year-over-year and is expected to continue declining in 2026 due to generic competition and pricing pressure.
− R&D expense rose to $14.1 million from $11.0 million year-over-year on higher clinical activity and headcount costs.
− Total revenue declined to $49.1 million from $62.5 million year-over-year due to lower Auryxia revenue.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Very High

Market backdrop VIX 16.4 · calm Equity put/call 0.57

Technical

price trend

Strong Sell

50 / 200-day cross No cross

Price vs 200-day avg −29%

below

Price vs 50-day avg −12%

below

RSI (14) 41

neutral

MACD trend Negative

52-week position 1%

near low

Momentum

relative strength

Very Weak

1-month return −11%

trailing

6-month return −38%

trailing

YTD return −46%

this year

Relative strength −50%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $1 › 200d $1 — 200d above 50d

Institutional flow Distributing

-1% holders QoQ · +37 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

7.40% of float · ▼ -10.9% MoM · 2.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

171 holders — mid 3-yr range

Squeeze score 53

elevated · 0–100

Fundamentals

Excellent

EPS growth +94%

Y/Y

Free cash flow $67.7M

Balance sheet $136.6M

net cash

Quant / Vol

risk profile

Very High

Volatility 78%

annualized · 1-yr

Max drawdown −73%

past year

ATR 6.3%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Prior guidance period ended · from the 8-K filed Jan 12, 2026

Vafseo net product revenue · Q4 2025 $5M – $6M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell

4 · 2 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−29% Bearish

Price vs 50-day avg

−12% Bearish

RSI (14)

41 Neutral

MACD trend

Negative Bearish

52-week position

1% Bearish

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $1 › 200d $1 — 200d above 50d

Institutional flow Distributing

-1% holders QoQ · +37 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

7.40% of float · ▼ -10.9% MoM · 2.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

171 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $1 Now $1 · 1% Range high $3

vs 200-day avg -29% vs 50-day avg -12%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
AKBA Akebia Therapeutics, Inc. this stock	$244.05M	-45.9%	+47.5%	—	7.4%
TAK Takeda Pharmaceutical Co Ltd	$60.23B	+14.6%	—	—	0.1%
GALDY Galderma Group AG/ADR	$46.00B	-6.4%	—	—	0.0%
TEVA Teva Pharmaceutical Industries Ltd	$45.67B	+26.0%	+4.3%	64.3	2.7%
HLN Haleon plc	$40.72B	-13.7%	—	—	0.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

171

% held: 39.3%
Net QoQ: +6.2M sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

138

View

Short & Settlement

Short Interest Falling

Shares short

20.5M

Days to cover: 2.8d
Change: -2.5M sh

View

Short Volume

Short vol %

69%

As of: Oct 1, 2026

Short Total

View

Fails to Deliver

FTD shares

1.3K

Value: $1.2K
As of: Sep 14, 2026

View

Off-Exchange

Off-exchange %

81.5%

Week of: Aug 24, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$236.2M

Net income (FY): $-5.3M
EPS diluted: $-0.02

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 5, 2026
This year: 13

View

Proposed Sales

Value

$62.2K

Shares: 56.0K
Filed: Jun 29, 2026

View

Earnings & Events

Webcasts

Last webcast

Aug 5, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
AKBA	-5.2%	-11.1%	-37.8%	-5.3%	-45.9%
SPY	-0.4%	-0.2%	+12.4%	+0.2%	+12.0%
vs SPY	-4.8%	-11.0%	-50.2%	-5.5%	-57.9%

Key facts CIK 1517022 CUSIP 00972D105 13F (30d) 4 filings 4 filers Visit website Investor relations

AKBA · Akebia Therapeutics, Inc.

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance